Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2024

Open Access 01-12-2024 | Cytokines | Research

Anti-inflammatory effect of curcuminoids and their analogs in hyperosmotic human corneal limbus epithelial cells

Authors: Ngamjit Kasetsuwan, Usanee Reinprayoon, Lita Uthaithammarat, Amornpun Sereemaspun, Nutchanart Sae-liang, Waraluck Chaichompoo, Apichart Suksamrarn

Published in: BMC Complementary Medicine and Therapies | Issue 1/2024

Login to get access

Abstract

Background

To assess the efficacy of curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin [BDC]) and their analogs (tetrahydrocurcumin [THC], tetrahydrodemethoxycurcumin [THDC], tetrahydrobisdemethoxycurcumin) in reducing inflammatory cytokines and their toxicity to primary human corneal limbal epithelial cells, these cells were cultured and exposed to these compounds.

Methods

The PrestoBlue assay assessed cell viability after treatment. Anti-inflammatory effects on hyperosmotic cells were determined using real-time polymerase chain reaction and significance was gauged using one-way analysis of variance and Tukey’s tests, considering p-values < 0.05 as significant.

Results

Curcuminoids and their analogs, at 1, 10, and 100 µM, exhibited no effect on cell viability compared to controls. However, cyclosporin A 1:500 significantly reduced cell viability more than most curcuminoid treatments, except 100 µM curcumin and BDC. All tested curcuminoids and analogs at these concentrations significantly decreased mRNA expression levels of tumor necrosis factor-α, interleukin (IL)-1β, IL-6, IL-17 A, matrix metallopeptidase-9, and intercellular adhesion molecule-1 after 90 mM NaCl stimulation compared to untreated cells. Furthermore, proinflammatory cytokine levels from hyperosmotic cells treated with 1, 10, and 100 µM curcumin, 100 µM BDC, 100 µM THC, 1 and 100 µM THDC mirrored those treated with cyclosporin A 1:500.

Conclusion

The anti-inflammatory efficiency of 1 and 10 µM curcumin, 100 µM THC, 1 and 100 µM THDC was comparable to that of cyclosporin A 1:500 while maintaining cell viability.
Appendix
Available only for authorised users
Literature
1.
go back to reference Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545–57.CrossRefPubMed Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. 2010;103:1545–57.CrossRefPubMed
2.
go back to reference Nebbioso M, Franzone F, Greco A, Gharbiya M, Bonfiglio V, Polimeni A. Recent advances and disputes about Curcumin in Retinal diseases. Clin Ophthalmol. 2021;15:2553–71.CrossRefPubMedPubMedCentral Nebbioso M, Franzone F, Greco A, Gharbiya M, Bonfiglio V, Polimeni A. Recent advances and disputes about Curcumin in Retinal diseases. Clin Ophthalmol. 2021;15:2553–71.CrossRefPubMedPubMedCentral
3.
go back to reference Allegrini D, Raimondi R, Borgia A et al. Curcumin in Retinal diseases: a Comprehensive Review from Bench to Bedside. Int J Mol Sci. 2022;23. Allegrini D, Raimondi R, Borgia A et al. Curcumin in Retinal diseases: a Comprehensive Review from Bench to Bedside. Int J Mol Sci. 2022;23.
4.
go back to reference Radkar P, Lakshmanan PS, Mary JJ, Chaudhary S, Durairaj SK. A novel multi-ingredient supplement reduces inflammation of the Eye and improves production and quality of tears in humans. Ophthalmol Ther. 2021;10:581–99.CrossRefPubMedPubMedCentral Radkar P, Lakshmanan PS, Mary JJ, Chaudhary S, Durairaj SK. A novel multi-ingredient supplement reduces inflammation of the Eye and improves production and quality of tears in humans. Ophthalmol Ther. 2021;10:581–99.CrossRefPubMedPubMedCentral
5.
go back to reference Trivedi MK, Panda P, Sethi KK, Gangwar M, Mondal SC, Jana S. Solid and liquid state characterization of tetrahydrocurcumin using XRPD, FT-IR, DSC, TGA, LC-MS, GC-MS, and NMR and its biological activities. J Pharm Anal. 2020;10:334–45.CrossRefPubMedPubMedCentral Trivedi MK, Panda P, Sethi KK, Gangwar M, Mondal SC, Jana S. Solid and liquid state characterization of tetrahydrocurcumin using XRPD, FT-IR, DSC, TGA, LC-MS, GC-MS, and NMR and its biological activities. J Pharm Anal. 2020;10:334–45.CrossRefPubMedPubMedCentral
6.
go back to reference Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des. 2013;19:2047–69.PubMedPubMedCentral Vyas A, Dandawate P, Padhye S, Ahmad A, Sarkar F. Perspectives on new synthetic curcumin analogs and their potential anticancer properties. Curr Pharm Des. 2013;19:2047–69.PubMedPubMedCentral
7.
go back to reference Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.CrossRefPubMed Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–83.CrossRefPubMed
8.
go back to reference Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575–628.CrossRefPubMed Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15:575–628.CrossRefPubMed
9.
go back to reference Nebbioso M, Fameli V, Gharbiya M, Sacchetti M, Zicari AM, Lambiase A. Investigational drugs in dry eye disease. Expert Opin Investig Drugs. 2016;25:1437–46.CrossRefPubMed Nebbioso M, Fameli V, Gharbiya M, Sacchetti M, Zicari AM, Lambiase A. Investigational drugs in dry eye disease. Expert Opin Investig Drugs. 2016;25:1437–46.CrossRefPubMed
10.
go back to reference Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45:941–56.CrossRefPubMed Changtam C, de Koning HP, Ibrahim H, Sajid MS, Gould MK, Suksamrarn A. Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species. Eur J Med Chem. 2010;45:941–56.CrossRefPubMed
11.
go back to reference Tocharus J, Jamsuwan S, Tocharus C, Changtam C, Suksamrarn A. Curcuminoid analogs inhibit nitric oxide production from LPS-activated microglial cells. J Nat Med. 2012;66:400–5.CrossRefPubMed Tocharus J, Jamsuwan S, Tocharus C, Changtam C, Suksamrarn A. Curcuminoid analogs inhibit nitric oxide production from LPS-activated microglial cells. J Nat Med. 2012;66:400–5.CrossRefPubMed
12.
go back to reference Ohtsu H, Xiao Z, Ishida J, et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem. 2002;45:5037–42.CrossRefPubMed Ohtsu H, Xiao Z, Ishida J, et al. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem. 2002;45:5037–42.CrossRefPubMed
13.
go back to reference Lee SL, Huang WJ, Lin WW, Lee SS, Chen CH. Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg Med Chem. 2005;13:6175–81.CrossRefPubMed Lee SL, Huang WJ, Lin WW, Lee SS, Chen CH. Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg Med Chem. 2005;13:6175–81.CrossRefPubMed
14.
go back to reference Portes E, Gardrat C, Castellan A. A comparative study on the antioxidant properties of tetrahydrocurcuminoids and curcuminoids. Tetrahedron. 2007;63:9092–9.CrossRef Portes E, Gardrat C, Castellan A. A comparative study on the antioxidant properties of tetrahydrocurcuminoids and curcuminoids. Tetrahedron. 2007;63:9092–9.CrossRef
15.
go back to reference Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010;90:437–43.CrossRefPubMed Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010;90:437–43.CrossRefPubMed
16.
go back to reference Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.CrossRefPubMed Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.CrossRefPubMed
17.
go back to reference Roda M, Corazza I, Bacchi Reggiani ML et al. Dry Eye Disease and tear cytokine Levels-A Meta-analysis. Int J Mol Sci. 2020;21. Roda M, Corazza I, Bacchi Reggiani ML et al. Dry Eye Disease and tear cytokine Levels-A Meta-analysis. Int J Mol Sci. 2020;21.
19.
go back to reference Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.PubMedPubMedCentral Haber SL, Benson V, Buckway CJ, Gonzales JM, Romanet D, Scholes B. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:2515841419870366.PubMedPubMedCentral
20.
go back to reference Liu XF, Hao JL, Xie T, et al. Curcumin, a potential therapeutic candidate for Anterior Segment Eye diseases: a review. Front Pharmacol. 2017;8:66.PubMedPubMedCentral Liu XF, Hao JL, Xie T, et al. Curcumin, a potential therapeutic candidate for Anterior Segment Eye diseases: a review. Front Pharmacol. 2017;8:66.PubMedPubMedCentral
21.
go back to reference Zhang ZB, Luo DD, Xie JH, et al. Curcumin’s metabolites, Tetrahydrocurcumin and Octahydrocurcumin, Possess Superior anti-inflammatory effects in vivo through suppression of TAK1-NF-κB pathway. Front Pharmacol. 2018;9:1181.CrossRefPubMedPubMedCentral Zhang ZB, Luo DD, Xie JH, et al. Curcumin’s metabolites, Tetrahydrocurcumin and Octahydrocurcumin, Possess Superior anti-inflammatory effects in vivo through suppression of TAK1-NF-κB pathway. Front Pharmacol. 2018;9:1181.CrossRefPubMedPubMedCentral
22.
go back to reference Yoysungnoen B, Bhattarakosol P, Patumraj S, Changtam C. Effects of tetrahydrocurcumin on hypoxia-inducible factor-1α and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice. Biomed Res Int. 2015;2015:391748.CrossRefPubMedPubMedCentral Yoysungnoen B, Bhattarakosol P, Patumraj S, Changtam C. Effects of tetrahydrocurcumin on hypoxia-inducible factor-1α and vascular endothelial growth factor expression in cervical cancer cell-induced angiogenesis in nude mice. Biomed Res Int. 2015;2015:391748.CrossRefPubMedPubMedCentral
23.
go back to reference Chen BL, Chen YQ, Ma BH, et al. Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Rα-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice. Clin Exp Allergy. 2018;48:1494–508.CrossRefPubMed Chen BL, Chen YQ, Ma BH, et al. Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Rα-Jak1-STAT6 and Jagged1/Jagged2 -Notch1/Notch2 pathways in asthmatic mice. Clin Exp Allergy. 2018;48:1494–508.CrossRefPubMed
24.
go back to reference Pan Y, Zhang Y, Yuan J, et al. Tetrahydrocurcumin mitigates acute hypobaric hypoxia-induced cerebral oedema and inflammation through the NF-κB/VEGF/MMP-9 pathway. Phytother Res. 2020;34:2963–77.CrossRefPubMed Pan Y, Zhang Y, Yuan J, et al. Tetrahydrocurcumin mitigates acute hypobaric hypoxia-induced cerebral oedema and inflammation through the NF-κB/VEGF/MMP-9 pathway. Phytother Res. 2020;34:2963–77.CrossRefPubMed
25.
go back to reference Park S, Lee LR, Seo JH, Kang S. Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats. Genes Nutr. 2016;11:2.CrossRefPubMedPubMedCentral Park S, Lee LR, Seo JH, Kang S. Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats. Genes Nutr. 2016;11:2.CrossRefPubMedPubMedCentral
26.
go back to reference Kim JE, Kim HR, Kim JC, et al. Tetrahydrocurcumin ameliorates skin inflammation by modulating Autophagy in High-Fat Diet-Induced obese mice. Biomed Res Int. 2021;2021:6621027.CrossRefPubMedPubMedCentral Kim JE, Kim HR, Kim JC, et al. Tetrahydrocurcumin ameliorates skin inflammation by modulating Autophagy in High-Fat Diet-Induced obese mice. Biomed Res Int. 2021;2021:6621027.CrossRefPubMedPubMedCentral
27.
go back to reference Stanić Z. Curcumin, a compound from natural sources, a true scientific challenge - A review. Plant Foods Hum Nutr. 2017;72:1–12.CrossRefPubMed Stanić Z. Curcumin, a compound from natural sources, a true scientific challenge - A review. Plant Foods Hum Nutr. 2017;72:1–12.CrossRefPubMed
28.
go back to reference Granata G, Paterniti I, Geraci C, et al. Potential Eye Drop based on a Calix[4]arene Nanoassembly for Curcumin Delivery: enhanced Drug Solubility, Stability, and anti-inflammatory effect. Mol Pharm. 2017;14:1610–22.CrossRefPubMed Granata G, Paterniti I, Geraci C, et al. Potential Eye Drop based on a Calix[4]arene Nanoassembly for Curcumin Delivery: enhanced Drug Solubility, Stability, and anti-inflammatory effect. Mol Pharm. 2017;14:1610–22.CrossRefPubMed
29.
go back to reference Pandey A, Chaturvedi M, Mishra S, Kumar P, Somvanshi P, Chaturvedi R. Reductive metabolites of curcumin and their therapeutic effects. Heliyon. 2020;6:e05469.CrossRefPubMedPubMedCentral Pandey A, Chaturvedi M, Mishra S, Kumar P, Somvanshi P, Chaturvedi R. Reductive metabolites of curcumin and their therapeutic effects. Heliyon. 2020;6:e05469.CrossRefPubMedPubMedCentral
30.
go back to reference Kao YW, Hsu SK, Chen JY et al. Curcumin Metabolite Tetrahydrocurcumin in the treatment of Eye diseases. Int J Mol Sci. 2020;22. Kao YW, Hsu SK, Chen JY et al. Curcumin Metabolite Tetrahydrocurcumin in the treatment of Eye diseases. Int J Mol Sci. 2020;22.
Metadata
Title
Anti-inflammatory effect of curcuminoids and their analogs in hyperosmotic human corneal limbus epithelial cells
Authors
Ngamjit Kasetsuwan
Usanee Reinprayoon
Lita Uthaithammarat
Amornpun Sereemaspun
Nutchanart Sae-liang
Waraluck Chaichompoo
Apichart Suksamrarn
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2024
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-024-04448-8

Other articles of this Issue 1/2024

BMC Complementary Medicine and Therapies 1/2024 Go to the issue